Veracyte VCYT 深 滬
等待開盤 09-18 09:30:00 美东时间
40.57
+2.070
+5.38%
華盛通- 最 高40.70
- 今 開39.67
- 成交量 147.03万股
- 最 低 38.80
- 昨 收 38.50
- 總市值 32.61亿
- 52周最高 60.91
- 市盈率 靜 49.27
- 換手率 1.83%
- 52周最低 29.455
- 委 比 34.19%
- 總股本 8039.07万
- 歷史最高 86.03
- 量 比 1.17
- 振 幅 4.94%
- 歷史最低 4.21
- 每 手 1
- 風險率 7.63%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Veracyte acquiring Convergent Genomics in up to $180M deal
Veracyte (VCYT) has agreed to buy Convergent Genomics, which is focused on urologic cancer diagnostics, for $150M upfront. The acquisition gives Veracyte, which provides cancer genomic tests, access t...
09-15 04:32
Veracyte Acquires Convergent Genomics, Expanding its Urology Diagnostics Portfolio with a Urinary Tumor DNA Testing Platform
Veracyte, a leading cancer diagnostics company, announced the acquisition of Convergent Genomics, gaining access to their UroAmp platform, which uses proprietary utDNA technology to improve bladder cancer care. UroAmp analyzes tumor-derived genomic information from urine, offering insights for therapy-response monitoring and post-treatment surveillance, particularly for non-muscle invasive bladder cancer (NMIBC). The acquisition strengthens Verac...
09-14 20:05
美股大行评级 | 戴尔、Adobe获大行上调目标价；甲骨文绩前目标价遭调低
今日重点评级关注：富国银行：维持Pyxis Oncology"超配"评级，目标价从12美元升至19美元；Oppenheimer：维持Opus Genetics"跑赢大市"评级，目标价从10美元升至20美元
09-10 15:00
UBS Maintains Buy on Veracyte, Raises Price Target to $65
UBS analyst Doug Schenkel maintains Veracyte (NASDAQ:VCYT) with a Buy and raises the price target from $52 to $65.
09-10 02:01
Cathie Wood's weekly recap: loads Rocket Lab, Block; cuts Palantir, Tempus AI
Cathie Wood’s Ark Invest leaned further into high-growth themes, including space, fintech, crypto, and biotechnology, during the last week while trimming several large technology and healthcare positi...
09-07 19:10
Veracyte to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference
Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, announced its participation in a fireside chat at the Morgan Stanley 24th Annual Global Healthcare Conference on September 15, 2026. The event will be webcast live at 7:00 a.m. Eastern Time, accessible via Veracyte’s website at http://investor.veracyte.com/events-presentations. A replay will be available for 90 days post-broadcast. Veracyte specializes in molecular tests that as...
09-01 20:05
Top 3 Health Care Stocks That Could Blast Off This Month
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies. The RSI is a momentum indicator, which compares a stock’s strength on days when prices go up to its strength on days when prices go down. When compared to a stock’s price action, it can give...
08-19 18:30
美股大行评级 | 潜在涨幅3586.64%！HC Wainwright上调Enlivex目标价至80美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持Enlivex"买入"评级，目标价从20美元升至80美元；Canaccord Genuity：维持Pharming Group NV Sponsored ADR"买入"评级，目标价从37美元升至38美元
08-04 11:45
美股大行评级 | 最高400美元！亚马逊绩后获11家大行上调目标价；苹果绩后评级分歧大！3家上调，3家下调；德康医疗、万事达、神经分泌生物科学获多家大行上调目标价
今日重点评级关注：TD Cowen：维持加拿大鹅"买入"评级，目标价从13美元升至18美元；瑞银：维持吉登运动服"买入"评级，目标价从110美元升至111美元
08-03 11:38
财报速睇 | Veracyte 2026财年Q2营收1.50亿美元，同比增长15.5%；归母净利润0.25亿美元，扭亏为盈
华盛资讯8月1日讯，Veracyte公布2026财年Q2业绩，公司Q2营收1.50亿美元，同比增长15.5%，归母净利润0.25亿美元，扭亏为盈。
08-01 06:21
